This month marks the 100-year anniversary of BCG, still the only approved vaccine against the lethal pathogen. But there are new vaccines for this wily foe on the horizon.

In the armpit lymph nodes of people who had received the mRNA vaccine against SARS-CoV-2, researchers found germinal centers needed to generate long-lived antibody-making cells.

Death rates among blood cancer patients who contract COVID-19 are higher than for those with other cancers, pointing to impaired immunity that makes it hard to overcome the virus.

Half a year after infection, people who had recovered from COVID-19 had robust antibodies, along with traces of the virus in their gut, which may drive long-lasting immunity.

Outcomes in COVID-19 patients may be better in those recently infected with endemic coronaviruses. 

An absence of germinal centers—which arise during infections to produce long-lived antibody-generating cells—might explain rapidly waning antibody levels in the disease.

A B-cell receptor critical for the production of a subset of intestinal antibodies has been pinpointed, but the function of those antibodies remains unclear.

Scientists are examining the role of T cells, which are likely crucial for long-term protection against SARS-CoV-2.

Studies are underway to test whether giving a shot of BCG vaccine could protect doctors and nurses against COVID-19.

Studies from serum samples could transform our understanding of the spread of COVID-19, but what antibodies alone say about immunity is not yet clear.

A small study of macaques finds they don’t develop a coronavirus infection the second time they are exposed, supporting the idea of using plasma from recovered patients as a treatment for COVID-19.

The 2019 Lasker medical and research awards celebrate advances in scientists’ understanding of T and B cells, Herceptin antibodies for treating breast cancer, and vaccine coverage around the globe.

A rogue hybrid lymphocyte, bearing characteristics of both B and T cells, may play a role in driving autoimmunity in the disease, although the mechanism is far from clear.

In line with previous research, a new study in mice demonstrates that B cells can be engineered to ward off infections, this time against respiratory syncytial virus (RSV).

An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.

Researchers report they’ve found a way to restore immune function in infants with one form of “bubble boy disease.”